Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Inpefa® (sotagliflozin) – New drug approval
May 26, 2023 - Lexicon Pharmaceuticals announced the FDA approval of Inpefa (sotagliflozin), to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure, and urgent heart failure visit in adults.
